Reuters logo
FDA approves Regeneron, Sanofi eczema drug
March 28, 2017 / 3:42 PM / 9 months ago

FDA approves Regeneron, Sanofi eczema drug

March 28 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA’s Dupixent for treatment of moderate to severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.

Atopic dermatitis is a type of skin inflammation also known as eczema, which in severe cases causes intense constant itching.

Reporting By Deena Beasley and Bill Berkrot; Editing by Chizu Nomiyama

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below